Phase II Study of GM-CSF Secreting Allogeneic Pancreatic Cancer Vaccine in Combination With PD-1 Blockade Antibody (Pembrolizumab) and Stereotactic Body Radiation Therapy (SBRT) for the Treatment of Patients With Locally Advanced Adenocarcinoma of the Pancreas
Summary
3/19/2020 NOTE: This trial currently has a waiting list.
The purpose of this study is to determine whether combining cyclophosphamide, pembrolizumab, GVAX, and SBRT is effective and safe in patients with locally advanced pancreatic cancer.
General Information
NCT#: NCT02648282
Study ID: J15237
Trial Phase: Phase II
Trial Sponsor: Sidney Kimmel Comprehensive Cancer Center
Therapies Used in This Trial: Stereotactic body radiotherapy (SBRT), GVAX, Cyclophosphamide, Pembrolizumab